Cardiovascular protective properties of incretin-based therapies in type 2 diabetes

Current Opinion in Lipidology

Volumn 23, Issue 6, 2012, Pages 540-547

  Simsek, Suat ^a,b   De Galan, Bastiaan E ^c  

^a Medical Centre Alkmaar   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

dipeptidyl peptidase 4 inhibitor; glucagon like peptide 1; insulin resistance; obesity; type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; APOLIPOPROTEIN B48; CASPASE 3; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROPRUSSIDE SODIUM; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SAXAGLIPTIN; SITAGLIPTIN; SUBSTANCE P; TOLL LIKE RECEPTOR 4; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VILDAGLIPTIN;

ADIPOSE TISSUE; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD FLOW VELOCITY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VESSEL; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIURESIS; DRUG EFFECT; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; FATTY ACID OXIDATION; FEMORAL ARTERY FLOW; FOREARM BLOOD FLOW; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY TUBULE ABSORPTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIPOGENESIS; LIPOPROTEIN METABOLISM; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; MORTALITY; MULTICENTER STUDY (TOPIC); NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPREGULATION; VASCULAR RESISTANCE; VASODILATATION;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; INCRETINS; RECEPTORS, GLUCAGON;

ANIMALIA;

EID: 84870049055     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283590b8f     Document Type: Review

References (62)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
2. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
3. Reijmer YD, van den Berg E, Ruis C, et al. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab Res Rev 2010; 26:507-519.
4. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 2007; 7:373-380. (Pubitemid 47422778)
5. Strachan MW, Reynolds RM, Marioni RE, Price JF. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 2011; 7:108-114.
6. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2:120-126. (Pubitemid 9238733)
7. Pan WH, Cedres LB, Liu K, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986; 123:504-516. (Pubitemid 16101155)
8. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol 1992; 45:1327-1334.
9. You RX, McNeil JJ, O'Malley HM, et al. Risk factors for stroke due to cerebral infarction in young adults. Stroke 1997; 28:1913-1918. (Pubitemid 27458995)
10. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234. (Pubitemid 28350165)
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471. (Pubitemid 46919772)
12. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-165.
13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157. (Pubitemid 46711096)
14. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (noninsulin-dependent) diabetes. Diabetologia 1986; 29:46-52. (Pubitemid 16162741)
15. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705. (Pubitemid 46048557)
16. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33:187-215. Comprehensive review on the underlying mechanisms by which GLP-1-based treatments may impact on the cardiovascular system.
17. Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Eur J Intern Med 2009; 20 (SUPPL. 2):S319-S328.
18. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011; 13:302-312.
19. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012; 109:1681-1685.
20. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 2012; 9:109-116.
21. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011; 55:10-16.
22. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58:975-983.
23. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109:962-965. (Pubitemid 38282847)
24. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100:824-829. (Pubitemid 47268274)
25. Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33:1491-1499. Elegant study showing how GLP-1 treatment may benefit patients after myocardial infarction.
26. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 2012; 98:408-413.
27. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:E1209-E1215. (Pubitemid 39491964)
28. Gaspari T, Liu H, Welungoda I, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diab Vasc Dis Res 2011; 8:117-124.
29. Chai W, Dong Z, Wang N, et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012; 61:888-896. This study shows that metabolic and cardiovascular effects of GLP-1 treatment may share common pathways mediated by nitric oxide effects on the microvasculature.
30. Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293:E1289-E1295. (Pubitemid 350106596)
31. Ha SJ, Kim W, Woo JS, et al. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol 2012; 32:474-480.
32. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22:1137-1143. (Pubitemid 29293967)
33. Marre M, Shaw J, Brä ndle M, et al., LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26:268-278.
34. Nauck M, Frid A, Hermansen K, et al., LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32:84-90.
35. Zinman B, Gerich J, Buse JB, et al., LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MetTZD). Diabetes Care 2009; 32:1224-1230.
36. Russell-Jones D, Vaag A, Schmitz O, et al., Liraglutide Effect and Action in Diabetes 5 (LEAD-5) metSU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 metSU): a randomised controlled trial. Diabetologia 2009; 52:2046-2055.
37. Buse JB, Rosenstock J, Sesti G, et al., LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47.
38. Vilsbøll T, Garber AJ. Nonglycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab 2012; 14 (SUPPL. 2):41-49.
39. Vilsbøll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.
40. Moreno C, Mistry M, Roman PJ. Renal effects of glucagon-like peptide 1 in rats. Eur J Pharmacol 2002; 434:163-167. (Pubitemid 34056575)
41. Chapman MJ, Ginsberg HN, Amarenco P, et al., European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32:1345-1361.
42. Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol 2012; 23:56-61.
43. Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010; 59:1063-1073.
44. Zaruba MM, Theiss HD, Vallaster M, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009; 4:313-323.
45. Hocher B, Sharkovska Y, Mark M, et al. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 2012 [Epub ahead of print].
46. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33:1607-1609.
47. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010; 3:195-201.
48. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48:592-598. (Pubitemid 351503521)
49. Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012; 14:561-567.
50. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010; 56:728-733. Interesting study showing potential interaction between DPP-IV inhibitors and ACE inhibitors on BP control in humans.
51. Jackson EK, Dubinion JH, Mi Z. Effects of dipeptidyl peptidase IV inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol 2008; 35:29-34. (Pubitemid 350197677)
52. Jackson EK. Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome. Hypertension 2010; 56:581-583.
53. Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223:133-135.
54. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Lancet 2010; 375:1447-1456.
55. Pratley R, Nauck M, Bailey T, et al., 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65:397-407.
56. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30:890-895. (Pubitemid 46556583)
57. Monami M, Lamanna C, Desideri CM, Manucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012; 29:14-25.
58. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012; 55:915-925.
59. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124:2338-2349.
60. Ta NN, Li Y, Schuyler CA, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010; 213:429-435.
61. Ta NN, Schuyler CA, Li Y, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58:157-166.
62. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011; 34:2072-2077.